A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer.
Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Yuan(Ministry of Ecology and Environment), Jinɡjinɡ Li(Sinopec (China)), Yanping Liu(Shijiazhuang Yiling Pharmaceutical (China)), Qi Xu(China Jiliang University), Yiwen Zhuo(Zhejiang Chinese Medical University), Xiangdong Cheng(Zhejiang Cancer Hospital)
Cited by 0
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412